Citigroup
LXRX icon

Citigroup’s Lexicon Pharmaceuticals LXRX Stock Holding History

Citigroup’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,000
Closed -$4K – 7705
2019
Q4 		$4K Hold
1,000
– – ﹤0.01% 7454
2019
Q3 		$3K Sell
1,000
-400
-29% -$1.24K ﹤0.01% 7467
2019
Q2 		$9K Sell
1,400
-12,100
-90% -$72.4K ﹤0.01% 7339
2019
Q1 		$75K Buy
13,500
+6,300
+88% +$38.3K ﹤0.01% 6002
2018
Q4 		$48K Sell
7,200
-10,400
-59% -$84.3K ﹤0.01% 6278
2018
Q3 		$188K Sell
17,600
-1,400
-7% -$16K ﹤0.01% 5320
2018
Q2 		$228K Buy
19,000
+13,500
+245% +$138K ﹤0.01% 4925
2018
Q1 		$47K Buy
5,500
+1,900
+53% +$17.6K ﹤0.01% 6211
2017
Q4 		$36K Sell
3,600
-19,200
-84% -$199K ﹤0.01% 6394
2017
Q3 		$280K Buy
22,800
+21,500
+1,654% +$318K ﹤0.01% 4689
2017
Q2 		$21K Sell
1,300
-24,800
-95% -$384K ﹤0.01% 6248
2017
Q1 		$374K Buy
26,100
+14,400
+123% +$214K ﹤0.01% 4115
2016
Q4 		$162K Buy
11,700
+11,500
+5,750% +$185K ﹤0.01% 5457
2016
Q3 		$4K Buy
+200
New +$3.22K ﹤0.01% 6825

Other funds holding LXRX

AG
Artal Group Luxembourg $687M AUM 17.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Compagnie Lombard Odier SCmA
Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $9.8B AUM 25.65% 1-Year Est. Return

Citigroup's LXRX Position: Q3 2026 in Review

Citigroup reduced its Lexicon Pharmaceuticals (LXRX) stake by 12% in Q3 2026, selling an estimated $45.8K and leaving 154,665 shares worth $290K. The position accounts for ﹤0.01% of the portfolio, ranked #4040.

Citigroup first reported a position in LXRX in Q2 2013 and has held it in 54 quarters since. The position peaked at $2.86M in Q3 2018. 86 funds tracked by Wall St. Rank hold LXRX as of Q3 2026.

  • Citigroup held 154,665 shares of Lexicon Pharmaceuticals worth $290K as of Q3 2026.
  • Citigroup sold 20,540 Lexicon Pharmaceuticals shares in Q3 2026, an estimated $45.8K.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #4040 holding.
  • Citigroup first reported a position in Lexicon Pharmaceuticals in Q2 2013 and has held it in 54 quarters since.
  • Citigroup's Lexicon Pharmaceuticals position peaked at $2.86M in Q3 2018.
  • 86 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.